On this page
- Alamar Biosciences, Inc. IPO
- Avalyn Pharma Inc. IPO
- CapsoVision, Inc IPO
- Elmet Group Co. IPO
- Lb Pharmaceuticals Inc IPO
- Liberty Defense Holdings, Ltd. IPO
- Pacipic Nexus IntelliTech Group IPO
- Aspire Biopharma Holdings, Inc. IPO
- X-Energy, Inc. IPO
Alamar Biosciences, Inc. IPO
StatusPriced
TickerALMR
ExchangeNasdaq Global Select Market
Offering price$17.00
First filed2026-03-27
Filings4
Alamar Biosciences, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-03-27. It has amended it 2 times. It filed its final prospectus on 2026-04-17, at a public offering price of $17.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 3, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 1, 2026 | Leadership change: Robert Ragusa appointed, Director, and 1 more | — | Leadership changes | Source |
| August 13, 2026 | Stake report, Schedule 13G, by Yuling Luo | 6.4% of the class | 5%+ stakes | Source |
| August 11, 2026 | Stake report, Schedule 13G, by Qiming Corporate GP VI, Ltd | 10.2% of the class | 5%+ stakes | Source |
| July 7, 2026 | Stake report, Schedule 13D/A, by Sands Capital Life Sciences Pulse Fund II, L.P. | 6.1% of the class | 5%+ stakes | Source |
| July 2, 2026 | Stake report, Schedule 13G, by Daqing Cai | 7.2% of the class | 5%+ stakes | Source |
| April 23, 2026 | Stake report, Schedule 13D, by Illumina Innovation Fund II, L.P. | 9.6% of the class | 5%+ stakes | Source |
| April 23, 2026 | Stake report, Schedule 13D, by Sands Capital Life Sciences Pulse Fund II, L.P. | 6.3% of the class | 5%+ stakes | Source |
Our common stock has been approved for listing on The Nasdaq Global Select Market (“Nasdaq”) under the trading symbol “ALMR.”From the 424B4 filed 2026-04-17
This is an initial public offering of shares of common stock of Alamar Biosciences, Inc. We are offering 11,250,000 shares of our common stock to be sold in the offering.From the 424B4 filed 2026-04-17
The initial public offering price is $17.00 per share.From the 424B4 filed 2026-04-17
We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, for general corporate purposes, including working capital, operating expenses and capital expenditures.From the 424B4 filed 2026-04-17
For the years ended December 31, 2024 and 2025, we generated total revenue of $25.1 million and $74.2 million, respectively, representing year-over-year growth of 195%.From the S-1/A filed 2026-04-16
For the years ended December 31, 2024 and 2025, we incurred net losses of $47.1 million and $29.8 million, respectively.From the S-1/A filed 2026-04-16
Avalyn Pharma Inc. IPO
StatusPriced
TickerAVLN
ExchangeNasdaq Global Select Market
Offering price$18.00
First filed2026-04-08
Filings4
Avalyn Pharma Inc. filed a Form S-1 registration statement for an initial public offering on 2026-04-08. It has amended it 2 times. It filed its final prospectus on 2026-04-30, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 16, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Novo Holdings A/S | 8.8% of the class | 5%+ stakes | Source |
| August 11, 2026 | Stake report, Schedule 13G, by Norwest Venture Partners XV, LP | 5.1% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 13.2% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13D, by SR One Capital Management, LLC | 7.5% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13D, by SUVRETTA CAPITAL MANAGEMENT, LLC | 5.6% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G, by Perceptive Advisors LLC | 6% of the class | 5%+ stakes | Source |
| May 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 11.5% of the class | 5%+ stakes | Source |
Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “AVLN.”From the 424B4 filed 2026-04-30
This is the initial public offering of shares of common stock of Avalyn Pharma Inc. We are offering 16,666,667 shares of our common stock.From the 424B4 filed 2026-04-30
The initial public offering price per share is $18.00.From the 424B4 filed 2026-04-30
We currently intend to use the net proceeds we receive from this offering, together with our existing cash, cash equivalents, and marketable securities to fund the continued development of AP01 and AP02, our two clinical stage programs, and AP03, our preclinical stage program, as well as to fund research and development activities for additional programs, and the remainder for working capital and general corporate purposes.From the 424B4 filed 2026-04-30
Our net losses were $85.2 million and $49.7 million for the years ended December 31, 2025 and 2024, respectively.From the S-1/A filed 2026-04-29
CapsoVision, Inc IPO
StatusPriced
TickerCV
ExchangeNasdaq Capital Market
Offering price$5.00
First filed2025-05-09
Filings6
CapsoVision, Inc filed a Form S-1 registration statement for an initial public offering on 2025-05-09. It has amended it 3 times. It filed its final prospectus on 2025-07-03, at a public offering price of $5.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 2, 2026 | Leadership change: Joanne Imperial departs, Director | — | Leadership changes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by Eliyahou Harari | 10.2% of the class | 5%+ stakes | Source |
| April 15, 2026 | Stake report, Schedule 13G/A, by Shen Ching Hang | 12.8% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G/A, by CID Greater China Venture Capital Fund III, L.P. | — | 5%+ stakes | Source |
| December 22, 2025 | Stake report, Schedule 13G, by Shen Ching Hang | 8.5% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G, by Kioxia Corporation | 7.4% of the class | 5%+ stakes | Source |
| October 29, 2025 | Stake report, Schedule 13G, by CID Greater China Venture Capital Fund III, L.P. | 6.7% of the class | 5%+ stakes | Source |
| October 14, 2025 | Stake report, Schedule 13G, by Eliyahou Harari | 9.2% of the class | 5%+ stakes | Source |
Our common stock is listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “CV.” On April 16, 2026, the last reported sales price for our common stock was $5.40 per share.From the S-1 filed 2026-04-17
This is the initial public offering of CapsoVision, Inc. We are offering 5,500,000 shares of our common stock, par value $0.001 per share.From the 424B4 filed 2025-07-03
The initial public offering price is $5.00 per share.From the 424B4 filed 2025-07-03
We intend to use the net proceeds of this offering for general corporate purposes.From the 424B4 filed 2025-07-03
For the years ended December 31, 2023 and 2024 and the three months ended March 31, 2025, we incurred net losses of $11.3 million, $19.9 million and $5.4 million, respectively.From the S-1/A filed 2025-06-27
| Filed | What it is | Filing |
|---|---|---|
| 2025-05-09 | Registration statement filed | S-1 |
| 2025-05-30 | Registration statement amended | S-1/A |
| 2025-06-13 | Registration statement amended | S-1/A |
| 2025-06-27 | Registration statement amended | S-1/A |
| 2025-07-03 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-04-17 | Registration statement filed | S-1 |
Elmet Group Co. IPO
StatusPriced
TickerELMT
ExchangeNasdaq
Offering price$14.00
First filed2026-03-30
Filings3
Elmet Group Co. filed a Form S-1 registration statement for an initial public offering on 2026-03-30. It has amended it 1 time. It filed its final prospectus on 2026-04-23, at a public offering price of $14.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 14, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Needham Investment Management L.L.C. | 8.8% of the class | 5%+ stakes | Source |
| June 3, 2026 | Stake report, Schedule 13G/A, by Peter V. Anania | 18.03% of the class | 5%+ stakes | Source |
| May 4, 2026 | Stake report, Schedule 13G, by George P. Schott | 17.01% of the class | 5%+ stakes | Source |
| May 4, 2026 | Stake report, Schedule 13G, by NEEDHAM INVESTMENT MANAGEMENT LLC | 7.3% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Peter V. Anania | 36.03% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Scott W. Knoll | 5.18% of the class | 5%+ stakes | Source |
We have been approved to have our common stock listed on the Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ELMT.”From the 424B4 filed 2026-04-23
We are offering 8,571,428 shares of our common stock.From the 424B4 filed 2026-04-23
The initial public offering price per share of our common stock is $14.00.From the 424B4 filed 2026-04-23
Lb Pharmaceuticals Inc IPO
StatusPriced
TickerLBRX
ExchangeNasdaq Global Market
Offering price$15.00
First filed2025-08-22
Filings4
Lb Pharmaceuticals Inc filed a Form S-1 registration statement for an initial public offering on 2025-08-22. It has amended it 1 time. It filed its final prospectus on 2025-09-12, at a public offering price of $15.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 13, 2026 | Stake report, Schedule 13G/A, by JPMORGAN CHASE & CO. | 4.3% of the class | 5%+ stakes | Source |
| September 15, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 3, 2026 | Leadership change: Joseph M. Miller appointed, Chief Financial Officer | — | Leadership changes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by TCG Crossover GP II, LLC | 5% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.3% of the class | 5%+ stakes | Source |
| July 16, 2026 | Stake report, Schedule 13G, by JPMORGAN CHASE & CO | 5.2% of the class | 5%+ stakes | Source |
| June 10, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Caligan Partners LP | 5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Commodore Capital LP | 6.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by TCG Crossover GP II, LLC | 6.4% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by JPMORGAN CHASE & CO | 4.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 8.7% of the class | 5%+ stakes | Source |
The newest 12 of 23 records.
Our common stock has been approved for listing on the Nasdaq Global Market, or Nasdaq, under the symbol “LBRX.” We believe that upon the completion of this offering, we will meet the standards for listing on Nasdaq, and the completion of this offering is contingent upon such listing.From the 424B4 filed 2025-09-12
This is the initial public offering of LB Pharmaceuticals Inc. We are offering 19,000,000 shares of our common stock.From the 424B4 filed 2025-09-12
The initial public offering price is $15.00 per share.From the 424B4 filed 2025-09-12
We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents, to advance the clinical development of LB-102 to treat acute schizophrenia and bipolar depression and utilize the remainder for general corporate purposes.From the 424B4 filed 2025-09-12
For the years ended December 31, 2024 and 2023, and the six months ended June 30, 2025, our net losses were approximately $63.1 million, $6.3 million, and $10.2 million, respectively.From the S-1/A filed 2025-09-08
Liberty Defense Holdings, Ltd. IPO
StatusPriced
TickerSCAN
ExchangeNasdaq Capital Market
First filed2026-02-05
Filings7
Liberty Defense Holdings, Ltd. filed a Form F-1 registration statement for an initial public offering on 2026-02-05. It has amended it 5 times. It filed its final prospectus on 2026-04-21. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by AWM Investment Company, Inc. | 9.9% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13D, by Global Value Investment Corporation | 21.01% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G, by LYTTON LAURENCE W | 9.9% of the class | 5%+ stakes | Source |
Our Common Shares are currently listed on the TSX Venture Exchange (the “TSXV”) under the symbol “SCAN,” quoted on the OTCQB ® Venture Market (the “OTCQB”) under the symbol of “LDDFF” and listed on the Frankfurt Stock Exchange (the “FSE”) under the symbol of “4XS.” Our Common Shares have been approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the symbol “DETX,” and are expected to commence trading on Nasdaq on April 22, 2026.From the 424B4 filed 2026-04-21
We intend to use the net proceeds from this offering for working capital and other general corporate purposes, including commercialization of our HD-AIT Upgrade Kit, business development activities associated with the sale of HEXWAVE™ and recurring engineering and cost reduction efforts for next generation HEXWAVE™.From the 424B4 filed 2026-04-21
| Filed | What it is | Filing |
|---|---|---|
| 2026-02-05 | Registration statement filed (foreign issuer) | F-1 |
| 2026-02-20 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-03-06 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-03-20 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-03-27 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-03-30 | Registration statement amended (foreign issuer) | F-1/A |
| 2026-04-21 | Final prospectus filed: the offering is priced | 424B4 |
Pacipic Nexus IntelliTech Group IPO
StatusAmended
TickerPNIG
ExchangeNasdaq Capital Market
First filed2026-03-20
Filings3
Pacipic Nexus IntelliTech Group filed a Form F-1 registration statement for an initial public offering on 2026-03-20. It has amended it 2 times. As of its latest filing, on 2026-04-30, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
We will apply to have our Ordinary Shares listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “PNIG”.From the F-1/A filed 2026-04-30
This is the initial public offering of 5,000,000 Ordinary Shares (as defined below) of Pacipic Nexus IntelliTech Group (“Pacipic Nexus”).From the F-1/A filed 2026-04-30
We currently intend to use the net proceeds from this offering to (i) 40% for payment of deposits to be used for purchasing our inventories;From the F-1/A filed 2026-04-30
Our revenue increased by 66.8 % from HK$ 74.2 million for the year ended August 31, 2024 to HK$ 123.7 million (US$ 15.87 million) for the year ended August 31, 2025.From the F-1/A filed 2026-04-30
As a result of the above discussed, we recorded a net income of HK$6.3 million (US$ 0.8 million) for the year ended August 31, 2025, representing an increase of HK$ 3.4 million or 115.7 % from a net income of HK$2.9 million for the year ended August 31, 2024.From the F-1/A filed 2026-04-30
Aspire Biopharma Holdings, Inc. IPO
StatusAmended
First filed2025-04-09
Filings8
Aspire Biopharma Holdings, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-04-09. It has amended it 2 times. As of its latest filing, on 2026-04-10, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
For the three months ended September 30, 2025, total revenue was $1,941 and total cost of goods sold was $1,057.From the S-1 filed 2025-12-03
For the year ended December 31, 2024, we had a net loss of $16,259,167, which consisted of other expenses of $11,827,548, operating expenses of $4,088,671 and interest expense on debt discount of $891,624, offset by Interest earned on investments held in Trust Account of $548,676.From the S-1 filed 2025-12-03
| Filed | What it is | Filing |
|---|---|---|
| 2024-08-02 | Request to withdraw a registration (names Form S-4, not the IPO registration) | RW |
| 2025-04-09 | Registration statement filed | S-1 |
| 2025-05-13 | Registration statement filed | S-1 |
| 2025-09-18 | Registration statement filed | S-1 |
| 2025-09-26 | Registration statement amended | S-1/A |
| 2025-12-03 | Registration statement filed | S-1 |
| 2026-02-17 | Registration statement filed | S-1 |
| 2026-04-10 | Registration statement amended | S-1/A |
X-Energy, Inc. IPO
StatusPriced
TickerXE
ExchangeNasdaq
Offering price$23.00
First filed2026-03-20
Filings6
X-Energy, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-03-20. It has amended it 4 times. It filed its final prospectus on 2026-04-27, at a public offering price of $23.00 per share. Each fact below is quoted from the filing named with it.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 4, 2026 | Stake report, Schedule 13G, by JANE STREET GROUP, LLC | 5.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Kamal Seyed Ghaffarian | 25% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G, by Ares Partners Holdco LLC | 12.3% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by Amazon.com, Inc. | 22.9% of the class | 5%+ stakes | Source |
| July 17, 2026 | Stake report, Schedule 13G, by SEGRA CAPITAL MANAGEMENT, LLC | 5.3% of the class | 5%+ stakes | Source |
| May 4, 2026 | Stake report, Schedule 13G, by Kenneth Griffin | 6.8% of the class | 5%+ stakes | Source |
We have been approved to list our Class A common stock on the Nasdaq Stock Market LLC (“Nasdaq”), under the symbol “XE.”From the 424B4 filed 2026-04-27
This is the initial public offering of shares of Class A common stock of X-Energy, Inc. We are offering 44,254,659 shares of our Class A common stock.From the 424B4 filed 2026-04-27
The initial public offering price per share of our Class A common stock is $23.00 per share.From the 424B4 filed 2026-04-27
| Filed | What it is | Filing |
|---|---|---|
| 2026-03-20 | Registration statement filed | S-1 |
| 2026-04-03 | Registration statement amended | S-1/A |
| 2026-04-08 | Registration statement amended | S-1/A |
| 2026-04-15 | Registration statement amended | S-1/A |
| 2026-04-20 | Registration statement amended | S-1/A |
| 2026-04-27 | Final prospectus filed: the offering is priced | 424B4 |
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.